125 related articles for article (PubMed ID: 38471102)
1. Familial adversity: association with discontinuation of adjuvant hormone therapy and breast cancer prognosis.
Zeng E; He W; Sjölander A; Bergqvist J; Fang F; Czene K
J Natl Cancer Inst; 2024 Jun; 116(6):920-928. PubMed ID: 38471102
[TBL] [Abstract][Full Text] [Related]
2. Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients.
He W; Smedby KE; Fang F; Olsson H; Margolin S; Hall P; Czene K
J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28423398
[TBL] [Abstract][Full Text] [Related]
3. Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer.
He W; Fang F; Varnum C; Eriksson M; Hall P; Czene K
J Clin Oncol; 2015 Jul; 33(20):2262-9. PubMed ID: 26033800
[TBL] [Abstract][Full Text] [Related]
4. Racial Differences in Adjuvant Endocrine Therapy Use and Discontinuation in Association with Mortality among Medicare Breast Cancer Patients by Receptor Status.
Farias AJ; Du XL
Cancer Epidemiol Biomarkers Prev; 2017 Aug; 26(8):1266-1275. PubMed ID: 28515111
[No Abstract] [Full Text] [Related]
5. Good adherence to adjuvant endocrine therapy in early breast cancer - a population-based study based on the Swedish Prescribed Drug Register.
Lundgren C; Lindman H; Rolander B; Ekholm M
Acta Oncol; 2018 Jul; 57(7):935-940. PubMed ID: 29493327
[TBL] [Abstract][Full Text] [Related]
6. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.
Hershman DL; Kushi LH; Shao T; Buono D; Kershenbaum A; Tsai WY; Fehrenbacher L; Gomez SL; Miles S; Neugut AI
J Clin Oncol; 2010 Sep; 28(27):4120-8. PubMed ID: 20585090
[TBL] [Abstract][Full Text] [Related]
7. Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor-2-Negative Early Breast Cancer Without Chemotherapy.
Fu F; Yu L; Zeng B; Chen M; Guo W; Chen L; Lin Y; Hou J; Li J; Li Y; Li S; Chen X; Zhang W; Jin X; Cai W; Zhang K; Chen H; Qiu Y; Nie Q; Wang C; Jacobs L
JAMA Netw Open; 2022 Feb; 5(2):e2145934. PubMed ID: 35166783
[TBL] [Abstract][Full Text] [Related]
8. Concomitant Discontinuation of Cardiovascular Therapy and Adjuvant Hormone Therapy Among Patients With Breast Cancer.
He W; Zeng E; Sjölander A; Hübbert L; Hedayati E; Czene K
JAMA Netw Open; 2023 Jul; 6(7):e2323752. PubMed ID: 37459096
[TBL] [Abstract][Full Text] [Related]
9. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
10. Discontinuation of adjuvant hormone therapy among breast cancer patients not previously attending mammography screening.
He W; Eriksson L; Törnberg S; Strand F; Hall P; Czene K
BMC Med; 2019 Jan; 17(1):24. PubMed ID: 30700300
[TBL] [Abstract][Full Text] [Related]
11. Adherence to adjuvant endocrine therapy: is it a factor for ethnic differences in breast cancer outcomes in New Zealand?
Seneviratne S; Campbell I; Scott N; Kuper-Hommel M; Kim B; Pillai A; Lawrenson R
Breast; 2015 Feb; 24(1):62-7. PubMed ID: 25486877
[TBL] [Abstract][Full Text] [Related]
12. Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women.
Artignan J; Capmas P; Panjo H; Constantinou P; Pelletier-Fleury N
BMC Med; 2023 Nov; 21(1):463. PubMed ID: 38001491
[TBL] [Abstract][Full Text] [Related]
13. Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system.
Kroenke CH; Hershman DL; Gomez SL; Adams SR; Eldridge EH; Kwan ML; Ergas IJ; Kubo A; Kushi LH
Breast Cancer Res Treat; 2018 Aug; 170(3):623-631. PubMed ID: 29671113
[TBL] [Abstract][Full Text] [Related]
14. Treatment interruption and discontinuation of hormonal therapy in hormone receptor-positive breast cancer patients.
Mao D; Hachem H; Chang H; Dima D; Dower J; Wismer M; Erban JK; Freund KM; Parsons SK
Breast Cancer Res Treat; 2020 Dec; 184(3):665-674. PubMed ID: 32918658
[TBL] [Abstract][Full Text] [Related]
15. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study.
Wigertz A; Ahlgren J; Holmqvist M; Fornander T; Adolfsson J; Lindman H; Bergkvist L; Lambe M
Breast Cancer Res Treat; 2012 May; 133(1):367-73. PubMed ID: 22286315
[TBL] [Abstract][Full Text] [Related]
16. Association of Sarcopenia With Toxicity-Related Discontinuation of Adjuvant Endocrine Therapy in Women With Early-Stage Hormone Receptor-Positive Breast Cancer.
Saraf A; Tahir I; Hu B; Dietrich AW; Tonnesen PE; Sharp GC; Tillman G; Roeland EJ; Nipp RD; Comander A; Peppercorn J; Fintelmann FJ; Jimenez RB
Int J Radiat Oncol Biol Phys; 2024 Jan; 118(1):94-103. PubMed ID: 37506979
[TBL] [Abstract][Full Text] [Related]
17. Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data.
Lailler G; Memoli V; Le Bihan Benjamin C; Ben Diane MK; Lauzier S; Mancini J; Bousquet PJ; Bouhnik AD
Clin Breast Cancer; 2021 Aug; 21(4):e415-e426. PubMed ID: 33745868
[TBL] [Abstract][Full Text] [Related]
18. The therapy is making me sick: how online portal communications between breast cancer patients and physicians indicate medication discontinuation.
Yin Z; Harrell M; Warner JL; Chen Q; Fabbri D; Malin BA
J Am Med Inform Assoc; 2018 Nov; 25(11):1444-1451. PubMed ID: 30380083
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant Hormone Therapy-Related Hot Flashes Predict Treatment Discontinuation and Worse Breast Cancer Prognosis.
Zeng E; He W; Smedby KE; Czene K
J Natl Compr Canc Netw; 2022 Apr; 20(6):683-689.e2. PubMed ID: 35385829
[TBL] [Abstract][Full Text] [Related]
20. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer.
Hershman DL; Shao T; Kushi LH; Buono D; Tsai WY; Fehrenbacher L; Kwan M; Gomez SL; Neugut AI
Breast Cancer Res Treat; 2011 Apr; 126(2):529-37. PubMed ID: 20803066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
